HCP
STLN icon

Holt Capital Partners’s Starling Oncology STLN Stock Holding History

Holt Capital Partners’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$187K Hold
29,534
– – 0.02% 165
2026
Q2 		$160K Hold
29,534
– – 0.02% 165
2026
Q1 		$90.7K Hold
29,534
– – 0.01% 153
2025
Q4 		$105K Buy
+29,534
New +$110K 0.01% 151

Other funds holding STLN

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $234B AUM 43.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Wexford Capital
Wexford Capital West Palm Beach, Florida $763M AUM 59.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Holt Capital Partners's STLN Position: Q3 2026 in Review

Holt Capital Partners held its Starling Oncology (STLN) position steady in Q3 2026 at 29,534 shares worth $187K. The position accounts for 0.02% of the portfolio, ranked #165.

Holt Capital Partners first reported a position in STLN in Q4 2025 and has held it in 4 quarters since. 91 funds tracked by Wall St. Rank hold STLN as of Q3 2026.

  • Holt Capital Partners held 29,534 shares of Starling Oncology worth $187K as of Q3 2026.
  • Holt Capital Partners left its Starling Oncology share count unchanged in Q3 2026.
  • Starling Oncology made up 0.02% of Holt Capital Partners's portfolio in Q3 2026, its #165 holding.
  • Holt Capital Partners first reported a position in Starling Oncology in Q4 2025 and has held it in 4 quarters since.
  • 91 funds tracked by Wall St. Rank held Starling Oncology as of Q3 2026.

Based on Holt Capital Partners's 13F filing for Q3 2026, filed 10 Nov 2026.